TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines~* Subjects for whom the decision has already been made to initiate treatment with etanercept~Exclusion Criteria:~* Sepsis or risk of sepsis~* Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection~* Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study~* Pre-existing or recent onset CNS demyelinating disease.~* Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.~* Previous or ongoing treatment with etanercept~* Participation in other clinical or observational studies.~* Patients with psoriatic arthritis requiring continuous etanercept treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Patients with moderate to severe plaque psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sugar-replacement Sweeteners, and Blood Sugar Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* body mass index (BMI) over 30.~* Homeostasis model assessment of insulin resistance (HOMA-IR) \< or = 2.6~Exclusion Criteria:~* smoking or smoked within last six months~* pregnant or breastfeeding~* have malabsorptive syndromes~* intestinal inflammatory disease~* diabetes~* liver or kidney disease~* fructose intolerance~* consuming more than one can of diet beverage or one spoonful of non-nutritive sweeteners (e.g. sucralose, aspartame, or saccharine) a week.~* taking any medication that might affect metabolism or taste.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- water-sucralose (Type: EXPERIMENTAL): Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week).
- sucralose-water (Type: EXPERIMENTAL): Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20 to 80 years scheduled to receive neck dissection due to head and neck cancer~Exclusion Criteria:~* history of coagulation disorders~* prior radiation to the neck~* prior neck dissection~* declined to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ligusure assisted neck dissection (Type: ACTIVE_COMPARATOR): The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours.
- Conventional neck dissection (Type: OTHER): The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian female~* Age 40-59 years~* Serum creatinine \< 1.3 and estimated glomerular filtration rate (GRF) \> 60~* Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl)~* Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml)~* Normal 25-hydroxyvitamin D level (30 ng/ml or higher)~* For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion)~Exclusion Criteria:~* Non-caucasian~* Age under 40 and over 59 years~* Male~* Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) \< 60~* Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl)~* Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml)~* For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion)~* History of bone radiation~* History of Paget disease of bone~* History of bone malignancy or metastases~* History of allergy or sensitivity to Forteo

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- teriparatide control (Type: ACTIVE_COMPARATOR): control subject
- Teriparatide Patient (Type: EXPERIMENTAL): Patient with secondary hyperparathyroidism

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health as determined by the Investigator based on medical history, physical examination, and routine laboratory tests at a screening evaluation.~* Male or female, aged between 18 and 55 years inclusive~* Body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2~* Subject must provide written informed consent~* Serosuitable to the challenge virus.~Exclusion Criteria:~* History or evidence of any clinically significant or currently active major clinical illness.~* Any significant abnormality altering the anatomy of the nose or nasopharynx~* Any nasal or sinus surgery within six months of the study~* Abnormal lung function~* Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.~* Presence of cold like symptoms and/or fever on admission for the study~* History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks of the study~* History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PC786 (Type: EXPERIMENTAL): Repeat dose
- Placebo/vehicle (Type: PLACEBO_COMPARATOR): Repeat dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Body mass index equal to or above 30 kg/m\^2~* Stable body weight (less than 5% self-reported change during the previous 3 months)~* Diagnosis of moderate or severe obstructive sleep apnoea (OSA)~* Unwilling or unable to use continuous positive airway pressure (CPAP) (or other positive airway pressure) treatment. No CPAP (or other positive airway pressure) treatment for at least four weeks prior to screening~* Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, compliance to visit schedule and dietary advice and complete trial related questionnaires~Exclusion Criteria:~* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors or insulin within the last 3 months prior to screening~* Diagnosis of type 1 or type 2 diabetes per judgement of the investigator~* Glycosylated haemoglobin (HbA1c) equal to or above 6.5%~* Significant craniofacial abnormalities that may cause OSA~* Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator~* Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone within the previous 3 months prior to screening~* Obesity induced by drug treatment~* Treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine within the last 3 month prior to screening~* Previous surgical treatment for obesity~* Screening calcitonin equal to or above 50 ng/L~* Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial Medullary Thyroid Carcinoma~* Personal history of non-familial Medullary Thyroid Carcinoma~* History of chronic pancreatitis or idiopathic acute pancreatitis~* History of Major Depressive Disorder or suicide attempts~* Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure equal to or above 100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 3.0 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Primary open angle glaucoma and normotensive glaucoma patients who came to the outpatient clinic for regular glaucoma check-ups were enrolled.~* 2. Glaucoma was defined as the patients who had open angle confirmed by gonioscopy, optic nerve cupping (a vertical cup-disc ratio of \>0.6) and or notching of the neuroretinal rim and or retinal nerve fiber defects characteristics of glaucoma, and visual field defect(i.e., a glaucoma hemi-filed test result outside normal limits, a pattern standard deviation probability of \<5%, or a cluster of three or more non-edge points in location typical of glaucoma, all of which were depressed on a pattern deviation plot at a P level of \<5%, and at least one of which was depressed at a P level of \<1% on two consecutive visual field tests).~* 3. Normal tension glaucoma included criteria: repeated measurements of untreated IOP values of \< 21mmHg. Primary open angle glaucoma included criteria: repeated measurements of untreated IOP values of ≥ 22mmHg.~Exclusion Criteria:~* 1. Phakic and pseudophakic eyes.~* 2. eyes that had been taken vitrectomy, trabeculectomy, or surgery influenced IOP

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
- Group 2 (Type: EXPERIMENTAL): Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise as an Adjuvant to Aphasia Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-stroke aphasia~* at least 6 months post-stroke~* at least minimally intact auditory verbal comprehension~* pre-morbidly right handed~* native English speaker~Exclusion Criteria:~* contraindications for fMRI (metal implants, claustrophobia)~* inability to pass an exercise tolerance test~* significant depression~* uncorrected hearing or vision problems~* severe apraxia of speech~* regularly perform 20 minutes of cardiovascular exercise 3 times per week

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Aphasia therapy with an exercise adjuvant (Type: EXPERIMENTAL): Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
- Aphasia therapy with a stretching adjuvant (Type: PLACEBO_COMPARATOR): Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers Inclusion Criteria and Exclusion Criteria. (Limit: 15,000 characters.) Inclusion criteria~1. Males and females ≥ 18 and ≤ 80 years of age;~2. LDL_C during screening period met the following conditions: super high risk: LDL - C ≥1.4mmol/L (55 mg/dL); extremely high risk: LDL - C ≥1.8 mmol/L (70 mg/dL); risk: LDL - C ≥2.6 mmol/L (100 mg/dL); low risk: LDL - C ≥ 3.4 /mmol/L (130 mg/dL)~3. Fasting triglycerides ≤4.5 mmol/L;~Exclusion criteria~1. Known HoFH;~2. History of NYHA class III-IV heart failure;~3. History of uncontrolled arrhythmia, Unstable angina,MI, PCI,CABG, DVT or pulmonary embolism within 3 months.~4. Uncontrolled hypertension.~5. Uncontrolled diabetes mellitius (HbA1c\>8.0%）.~6. Other conditions that investigators considered inappropriate to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- JS002 (Type: EXPERIMENTAL): Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
- Placebo (Type: PLACEBO_COMPARATOR): Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 75 years of age, inclusive, at time of informed consent.~* Must have the following atopic dermatitis criteria:~  1. Have a clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year prior to Day 1 and has confirmed atopic dermatitis (Hanifin and Rajka criteria of AD refer to Appendix 2) at the Screening visit.~ 2. Have inadequate response to treatment with topical medications given for at least 4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks) within 12 months of the first dose of study drug.~ 3. Moderate to severe AD (affected BSA \>=10 %, IGA \>=3, and EASI \>=12 at the screening and baseline visits).~Exclusion Criteria:~* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,~* Infected with hepatitis B or hepatitis C viruses.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)~* Have received any of the following treatment regiments specified in the timeframes outlined below:~Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving investigational drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated live vaccine.~Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.~Within 1 week of first dose of study drug: Topical treatments that could affect atopic dermatitis; Herbal medications with unknown properties or known beneficial effects for AD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 10 mg of PF-04965842 QD
- Cohort 2 (Type: EXPERIMENTAL): 30 mg of PF-04965842 QD
- Cohort 3 (Type: EXPERIMENTAL): 100 mg of PF-04965842 QD
- Cohort 4 (Type: EXPERIMENTAL): 200 mg of PF-04965842 QD
- Cohort 5 (Type: PLACEBO_COMPARATOR): placebo QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Therapeutic Workplace Initiation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Baseline inclusion criteria:~* are at least 18 years of age~* are enrolled in methadone maintenance treatment in Baltimore~* provide a cocaine-positive urine sample at time of initial screening~* self-report cocaine use through intravenous route~* have visible evidence of intravenous drug use (i.e., track marks).~Baseline exclusion criteria:~* report current suicidal ideation~* if the individual reports hallucinations~* have physical limitations (e.g., broken fingers) that prevent the subject from typing.~* Applicants reporting hallucinations are excluded because this is a characteristic of a psychiatric disorder that is likely to result in behaviors that could disrupt the workplace or functioning or limit their ability to provide informed consent.~Main study inclusion criteria:~* have attended the workplace regularly during 4-week baseline periods~* are still in methadone maintenance treatment at the end of the 4-week baseline period~* have provided at least two urine samples that test positive for cocaine during the baseline period~* Individuals who are excluded from the main study will be allowed to complete their 8-week training program in the Therapeutic Workplace. They may also be invited to participate in other studies ongoing at the Center for Learning and Health where this research takes place.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abstinence & Work (Type: EXPERIMENTAL): Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
- Work Only (Type: OTHER): Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete